What is NDC 70436-231?

70436-231 is the product NDC for ganciclovir sodium, Ganciclovir sodium 500 mg/10mL injection, powder, lyophilized, for solution, listed with the FDA by Slate Run Pharmaceuticals, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.

Slate Run Pharmaceuticals, LLC, NDC labeler code 70436. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for ganciclovir sodium?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

ganciclovir sodium NDC 70436-231 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)70436-231Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70436-0231Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70436-231-55	7043602315570436023155	25 VIAL in 1 CARTON (70436-231-55) / 10 mL in 1 VIALMarketed from Sep 1, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): ganciclovir sodium
Generic name (nonproprietary): ganciclovir sodium
Active ingredients: Ganciclovir sodium — 500 mg/10mL
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intravenous
Labeler: Slate Run Pharmaceuticals, LLCNDC labeler code 70436
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 204204
Marketing start: Jan 1, 2019
Listing expires: Dec 31, 2026
Other FDA classes: DNA Polymerase Inhibitors (Mechanism)Nucleoside Analog (EXT)
Identifiers: Product ID 70436-231_2ac6c72f-6f19-825c-e063-6294a90af661SPL ID 2ac6c72f-6f19-825c-e063-6294a90af661SPL set ID cd293b9d-b573-4656-8574-19d7db870a9bRxCUI 310442UNII 02L083W284
Pharmacologic class: Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor; Nucleoside Analog Antiviral

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N470436023155 followed by a unit qualifier and the quantity

Package 70436-0231-55. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 2, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Ganciclovir for Injection, USP is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for the: Treatment of CMV retinitis in immunocompromised adult patients, including patients with acquired immunodeficiency syndrome (AIDS). ( 1.1 ) Prevention of CMV disease in adult transplant recipients at risk for CMV disease. ( 1.2 ) 1.1 Treatment of CMV Retinitis Ganciclovir for Injection, USP is indicated for the treatment of cytomegalovirus (CMV) retinitis in immunocompromised adult patients, including patients with acquired immunodeficiency syndrome (AIDS) [see Clinical Studies (14.1) ]. 1.2 Prevention of CMV Disease in Transplant Recipients Ganciclovir for Injection,…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 70436-231

What is NDC 70436-231?: 70436-231 is the product NDC for ganciclovir sodium, Ganciclovir sodium 500 mg/10mL injection, powder, lyophilized, for solution, listed with the FDA by Slate Run Pharmaceuticals, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: ganciclovir sodium.
What is the active ingredient?: Ganciclovir sodium.
Who is the labeler?: Slate Run Pharmaceuticals, LLC, NDC labeler code 70436. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for ganciclovir sodium?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other NDCs under ANDA 204204

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 204204
Product	Strength	Form · route	Labeler	Product NDC
ganciclovirganciclovir sodium	Ganciclovir sodium 500 mg/10mL	Injection, Powder, Lyophilized, For solutionIntravenous	Slate Run Pharmaceuticals, LLC	70436-089